TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03259516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 1 mg/kg by vein on Days 1 and 15 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid
Description: 45 mg/m2 per os daily during the whole course of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20 mg per os three times a day during the whole course of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 2 mg per os daily during the whole course of treatment
Study: NCT05556551

Intervention type: OTHER
Group type: OTHER
Intervention: Full Ceramic restoration
Description: Two different dental restoration inserted in patient mouth ( split mouth)
Study: NCT03717506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC 268 Lotion
Description: GDC 268 is a topical lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Phosphate Lotion 1%
Description: Clindamycin Phosphate Lotion is an FDA-approved drug product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GDC Vehicle Lotion
Description: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
Study: NCT04032353

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Consortium
Description: subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
Study: NCT02206750

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Study: NCT02250118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrapleural Bevacizumab
Study: NCT03122158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
Study: NCT03192215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81 mg by mouth once daily.
Study: NCT03783780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00031
Description: Noninvasive pulse oximeter sensor
Study: NCT00421070

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
Study: NCT02562781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen in sufficient quantity to maintain SpO2 \> 98%
Study: NCT05556551

Intervention type: OTHER
Group type: OTHER
Intervention: Hybrid resin Ceramic restoration
Description: Hybrid resin Ceramic restoration
Study: NCT01943318

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Histologic evaluation
Study: NCT00034528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
Study: NCT01943318

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Histologic evaluation

Intervention type: PROCEDURE
Intervention: Liver biopsy
Description: Histologic evaluation
Study: NCT02562781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen in sufficient quantity to maintain SpO2 \> 98%
Study: NCT02562781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Air
Description: Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Supplemental Oxygen in sufficient quantity to maintain SpO2 \> 90%
Study: NCT00159926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell saver
Description: Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No cell saver
Description: Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
Study: NCT00034528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: 0.15 mg/kg taken orally daily for 12 to 14 weeks
Study: NCT01862900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469
Description: Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 24 hour infusion
Study: NCT00034528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
Study: NCT01340859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Admission Cognitive Therapy (PACT)
Description: Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
Study: NCT01718041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: VRS-317
Description: Active treatment arm
Study: NCT02767765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-HuEPO
Description: All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
Study: NCT02887898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated bolus calculator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study: NCT04980274

Intervention type: OTHER
Intervention: Intervention focused on identified organ dysfunction(s)
Description: Intervention focused on identified organ dysfunction(s)

Intervention type: OTHER
Intervention: Intervention focused on identified organ dysfunction(s)
Description: Intervention focused on identified organ dysfunction(s)

Intervention type: OTHER
Intervention: Intervention focused on identified organ dysfunction(s)
Description: Intervention focused on identified organ dysfunction(s)
Study: NCT03311737

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: The investigators used general anesthesia preoperatively in uniportal VATS lung surgery

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: epidural anesthesia
Description: The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
Study: NCT01812096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous bortezomib
Study: NCT01647581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoclip Placement
Description: Placement of hemoclip at polypectomy site for polyps at least 1cm in size

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NO hemoclip placement
Description: No hemoclip placement (placebo / sham)
Study: NCT02263573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP'C-R
Description: Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE \* 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC \* 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group usual activities
Description: Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
Study: NCT02395744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paclitaxel administration using the OPC
Study: NCT01943318

Intervention type: DEVICE
Intervention: Hepatic venous pressure gradient (HVPG) measurement
Description: Hepatic venous pressure gradient (HVPG) measurement
Study: NCT03287622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
Study: NCT01761201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months.
Study: NCT04458454

Intervention type: DIAGNOSTIC_TEST
Intervention: Relaxin ELISA Kit
Description: Ovarian stimulation was carried out from day 3 of the menstrual cycle using a fixed protocol, with recombinant (Gonal-F, Pergoveris) or human menopausal gonadotropins (Meriofert), GnRH antagonist (ganirelix 0.25 mg). A recombinant human chorionic gonadotropin Ovitrel 250 μg or a GnRH agonist, Diferelin 0.2 mg, was used as an ovulation trigger.
Study: NCT01955226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tegaderm CHG clear dressing
Description: Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard clear Tegaderm dressing
Description: Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
Study: NCT01006434

Intervention type: OTHER
Intervention: Recording of body weight estimations, approximations and tPA dose
Description: Body weight estimation, patients are weighed, actual tPA dose is recorded

Intervention type: OTHER
Intervention: Recording of body weight estimations, approximations and tPA dose
Description: Body weight estimation, patients are weighed, actual tPA dose is recorded
Study: NCT04106869

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation
Description: Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (\<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoventilation
Description: Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg.
Study: NCT03002428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (PF708)
Description: Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide (Forteo)
Description: Subcutaneous injection
Study: NCT01943318

Intervention type: DEVICE
Intervention: Hepatic venous pressure gradient (HVPG) measurement
Description: Hepatic venous pressure gradient (HVPG) measurement

Intervention type: DEVICE
Intervention: Hepatic venous pressure gradient (HVPG) measurement
Description: Hepatic venous pressure gradient (HVPG) measurement
Study: NCT04038736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Scan System
Description: During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
Study: NCT02810236

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound will be performed.
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 24 hour infusion
Study: NCT02810236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Radiologist will discuss with the patient the findings on mammogram.
Study: NCT03928353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Sodium Chloride
Description: 30 minute - 24 hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
Study: NCT00621634

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fish oil capsules (including DHA)
Description: Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
Study: NCT01667341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 with Matrix M-2
Description: IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
Study: NCT00621634

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
Study: NCT02421185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493 (erdafitinib)
Description: Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1.
Study: NCT04085874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of Food-based recommendations
Description: Prolonged contact through weekly home visits and monthly group meeting for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling from standard health services care
Description: once nutrition counselling from health services
Study: NCT01667341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 with Matrix M-2
Description: IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003 with Matrix M-2
Description: IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN-003
Description: IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
Study: NCT04596683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Same-day NSM or SSM
Description: Discharge home same-day after nipple-sparing mastectomy (NSM), or skin-sparing mastectomy (SSM)
Study: NCT04118725

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary function test
Description: Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
Study: NCT02710877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed Intermittent bolus
Description: Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual epidural bolus
Description: Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Levobupivacaine 0,0625% through peridural catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Levobupivacaine 0,0625% through peridural catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil 4 mcg
Description: Sufentanil 0,4 mcg/ml through peridural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil 5 mcg
Description: Sufentanil 5 mcg through peridural catheter
Study: NCT04256239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Intervention aimed at enhancing patients' sense of personhood, purpose, meaning, and self-worth and reducing psychosocial and existential distress